Larimar Therapeutics Inc - Asset Resilience Ratio
Larimar Therapeutics Inc (LRMR) has an Asset Resilience Ratio of 10.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Larimar Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Larimar Therapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Larimar Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Larimar Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.47 Million | 10.78% |
| Total Liquid Assets | $22.47 Million | 10.78% |
Asset Resilience Insights
- Moderate Liquidity: Larimar Therapeutics Inc has 10.78% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Larimar Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Larimar Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Larimar Therapeutics Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Larimar Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.27% | $51.44 Million | $145.84 Million | -39.76pp |
| 2024-12-31 | 75.03% | $150.24 Million | $200.22 Million | +12.45pp |
| 2023-12-31 | 62.59% | $60.04 Million | $95.94 Million | -9.88pp |
| 2022-12-31 | 72.47% | $91.60 Million | $126.41 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $78.67 Million | -- |
| 2020-12-31 | 23.39% | $24.49 Million | $104.69 Million | -33.06pp |
| 2018-12-31 | 56.45% | $68.73 Million | $121.76 Million | -1.62pp |
| 2017-12-31 | 58.08% | $61.27 Million | $105.51 Million | -15.50pp |
| 2016-12-31 | 73.58% | $96.84 Million | $131.62 Million | -5.47pp |
| 2015-12-31 | 79.05% | $149.48 Million | $189.11 Million | +30.24pp |
| 2014-12-31 | 48.81% | $57.36 Million | $117.52 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.